A part of Merck

324880 | (–)-Epigallocatechin Gallate - CAS 989-51-5 - Calbiochem

324880
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmarDisponibilidad a confirmar
En existencia 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Ver precios y disponibilidad
      Click To Print This Page

      Descripción

      Replacement Information

      Tabla espec. clave

      Empirical FormulaCAS #
      C₂₂H₁₈O₁₁ 989-51-5

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      US1324880-10MG
      Comprobando disponibilidad...
      Disponibilidad a confirmarDisponibilidad a confirmar
      En existencia 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente

          Frasco de vidrio 10 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Description
          OverviewOne of the main polyphenolic constituents of green tea that exhibits potent antitumor, anti-inflammatory, and antioxidant properties. Arrests cell cycling at G0/G1 phase and induces apoptosis in a dose-dependent manner. Shown to inhibit PMA-induced skin thickening and to activate of protein kinase C. Also activates ornithine decarboxylase and interleukin-1α mRNA and protein expression. Acts as an inhibitor of inducible nitric oxide synthase (iNOS) gene expression and enzyme activity. Also blocks peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Strongly and directly inhibits telomerase in cell-free systems and in cancer cell lines. An inhibitor of Dnmt1 (IC50 = 210-470 nM). Acts as a selective and noncompetitive inhibitor of HAT activities (IC50 = 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60) with minimal effects on HDAC, SIRT and HMTase.
          Catalogue Number324880
          Brand Family Calbiochem®
          SynonymsEGCG, (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate), DNA Methyltransferase Inhibitor IV, DNA MTase Inhibitor IV, HAT Inhibitor X, Histone Acetyltransferase Inhibitor X, p300/CBP Inhibitor VIII, PCAF Inhibitor V
          References
          ReferencesChoi, K.C., et al. 2009. Cancer Res. 69, 583.
          Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
          Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
          Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
          Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
          Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
          Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
          Fiala, E.S., et al. 1996. Experientia 52, 922.
          Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
          Liao, S., et al. 1995. Cancer Lett. 96, 239.
          Yamane, T., et al. 1995. Cancer Res. 55, 2081.
          Huang, M.T., et al. 1992. Carcinogenesis 13, 947.
          Product Information
          CAS number989-51-5
          ATP CompetitiveN
          FormFaint pink solid
          Hill FormulaC₂₂H₁₈O₁₁
          Chemical formulaC₂₂H₁₈O₁₁
          ReversibleN
          Structure formula Image
          Applications
          Biological Information
          Primary TargetPMA-induced skin thickening
          Primary Target IC<sub>50</sub>210-470 nM against Dnmt1; 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSKB5200000
          Safety Information
          R PhraseR: 36/37/38

          Irritating to eyes, respiratory system and skin.
          S PhraseS: 26-36

          In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
          Wear suitable protective clothing.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. DMSO stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          Certificados de análisis

          CargoNúmero de lote
          324880

          Referencias bibliográficas

          Visión general referencias
          Choi, K.C., et al. 2009. Cancer Res. 69, 583.
          Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
          Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
          Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
          Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
          Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
          Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
          Fiala, E.S., et al. 1996. Experientia 52, 922.
          Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
          Liao, S., et al. 1995. Cancer Lett. 96, 239.
          Yamane, T., et al. 1995. Cancer Res. 55, 2081.
          Huang, M.T., et al. 1992. Carcinogenesis 13, 947.
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision05-August-2009 JSW
          SynonymsEGCG, (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate), DNA Methyltransferase Inhibitor IV, DNA MTase Inhibitor IV, HAT Inhibitor X, Histone Acetyltransferase Inhibitor X, p300/CBP Inhibitor VIII, PCAF Inhibitor V
          DescriptionOne of the main polyphenolic constituents of green tea that possesses potent antitumor, anti-inflammatory, and antioxidant properties. EGCG has been shown to inhibit PMA-induced skin thickening, activation of protein kinase C, activation of ornithine decarboxylase, and activation of interleukin-1α mRNA and protein expression. Has also been shown to inhibit inducible nitric oxide synthase (iNOS) gene expression and enzyme activity and to inhibit the peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Also strongly and directly inhibits telomerase. Acts as a selective and noncompetitive inhibitor of HAT activities (IC50 = 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60) with minimal effects on HDAC, SIRT and HMTase.
          FormFaint pink solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number989-51-5
          RTECSKB5200000
          Chemical formulaC₂₂H₁₈O₁₁
          Structure formula
          Purity≥95% by HPLC
          SolubilityDMSO or H₂O (5 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. DMSO stock solutions are stable for up to 3 months at -20°C.
          Toxicity Irritant
          Merck USA index14, 3526
          ReferencesChoi, K.C., et al. 2009. Cancer Res. 69, 583.
          Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
          Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
          Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
          Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
          Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
          Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
          Fiala, E.S., et al. 1996. Experientia 52, 922.
          Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
          Liao, S., et al. 1995. Cancer Lett. 96, 239.
          Yamane, T., et al. 1995. Cancer Res. 55, 2081.
          Huang, M.T., et al. 1992. Carcinogenesis 13, 947.